Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-21 + Sorafenib in Metastatic RCC
NCT00389285Phase 2Completed
- Sponsor
- ZymoGenetics
- Start
- Oct 2006
- Primary completion
- May 2009
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin 21 in renal cell carcinoma (RCC), sponsored by ZymoGenetics. Started Oct 2006; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00389285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389285.